drugset / Trial / NCT05260385
To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the preliminary efficacy, safety, tolerability and pharmacokinetics of KC1036 in participants with advanced recurrent or metastatic digestive system tumors.
Timeline
- Start
- 2022-01-24
- Primary completion
- 2025-10-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KC1036 | Unknown | 20 mg | Oral |
| Subject | KC1036 | Unknown | 30 mg | Oral |
| Subject | KC1036 | Unknown | 40 mg | Oral |
| Subject | KC1036 | Unknown | 60 mg | Oral |